The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Adverse reactions to first-line antituberculosis drugs
Abstract
INTRODUCTION: Tuberculosis continues to be a major cause of morbidity and mortality worldwide. Currently available drugs are effective for treatment of the disease or latent infection, but may cause serious adverse effects. METHODS: The authors reviewed the literature for side effects of five first-line antituberculous medications (isoniazid, rifampin, pyrazinamide, ethambutol and streptomycin). Incidence of the major side effects were compiled with particular attention to the incidence of isoniazid hepatotoxicity. RESULTS: Hepatotoxicity to isoniazid is a serious problem. Although overall incidence may be decreasing, incidence averaged 9.2 per 1000 patients who were compliant, in multiple studies, with a case fatality rate of 4.7%. The incidence is higher with increasing age. Other serious adverse effects include dermatological, gastrointestinal, hypersensitivity, neurological, haematological and renal reactions. They can lead to drug discontinuation (in up to 10% of patients) or even more serious morbidity or mortality. CONCLUSIONS: Side effects to antituberculosis drugs are common, and include hepatitis, cutaneous reactions, gastrointestinal intolerance, haematological reactions and renal failure. These adverse effects must be recognised early, to reduce associated morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.supplement_3.ats600 · Cited by 1,241
Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., & Menzies, D. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-626oc · Cited by 840
Self-citationControlled chemoprophylaxis trials in tuberculosis. A general review.
Sh, F. (1970) · PubMed · Cited by 721
Iuat (1982) · Bulletin of the World Health Organization · Cited by 515
Isoniazid Liver Injury: Clinical Spectrum, Pathology, and Probable Pathogenesis
MITCHELL, J. R., ZIMMERMAN, H. J., ISHAK, K. G., THORGEIRSSON, U. P., TIMBRELL, J. A., SNODGRASS, W. R., & NELSON, S. D. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-84-2-181 · Cited by 505
Toxic Hepatitis with Isoniazid and Rifampin
Steele, M. A., Burk, R. F., & DesPrez, R. M. (1991) · Chest · doi:10.1378/chest.99.2.465 · Cited by 437
Whalen, C. C., Johnson, J. L., Okwera, A., Hom, D. L., Huebner, R., Mugyenyi, P., Mugerwa, R. D., Ellner, J. J., Nsubuga, P., Vjecha, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371201 · Cited by 396
Schaberg, T., Rebhan, K., & Lode, H. (1996) · European Respiratory Journal · doi:10.1183/09031936.96.09102026 · Cited by 379
Cited by
Antituberculosis drugs: Ten years of research
Janin, Y. L. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.01.030 · Cited by 485
Devarbhavi, H., Dierkhising, R., Kremers, W. K., Sandeep, M. S., Karanth, D., & Adarsh, C. K. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.287 · Cited by 195
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
McDonagh, E. M., Boukouvala, S., Aklillu, E., Hein, D. W., Altman, R. B., & Klein, T. E. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000062 · Cited by 146
Devarbhavi, H., Singh, R., Patil, M., Sheth, K., Adarsh, C. K., & Balaraju, G. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07279.x · Cited by 86
Metadata
- Authors
- Forget, E. J., & Menzies, D.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2006-02-27
- Volume
- 5
- Issue
- 2
- Pages
- 231-249
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2012393743
- Cited by
- 315
- References
- 99
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adverse reactions to first-line antituberculosis drugs. https://app.cochat.ai/papers/10.1517/14740338.5.2.231
- The paper
- Forget, E. J., & Menzies, D. (2006). Adverse reactions to first-line antituberculosis drugs. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.5.2.231
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.